

vaccines - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
mRNA vaccine	66 studies ¹	-	-	0.50 [0.11 ; 2.28], 2 RCTs, I2=0% inconclusive result	-
Non replicating viral vector	34 studies ²	-	-	0.19 [0.06 ; 0.64], 2 RCTs, I2=0% moderate degree of certainty	-
first booster dose	20 studies ³	-	-	0.13 [0.08 ; 0.24], 6 studies, I2=78% high degree of certainty	-
Inactivated virus vaccine	12 studies ⁴	-	-	0.20 [0.14 ; 0.28], 1 study, I2=0% certainty unassessable	-
second booster dose	7 studies ⁵	-	-	0.22 [0.17 ; 0.28], 1 study, I2=0% certainty unassessable	-
protein subunit vaccine	4 studies ⁶	-	-	-	-
complete primary vaccine series	1 study ⁷	0.45 [0.34 ; 0.60], 3 studies, I2=66% certainty unassessable	-	0.16 [0.06 ; 0.41], 5 studies, I2=79% high degree of certainty	-
heterologous prime-boost	1 study ⁸	-	-	-	-

Notes

¹Haas, 2021 (emergency) ; BNT162b2 phase 3 (C4591001, Polack), 2020 (NCT04368728) ; COVE Moderna/NIH phase 3 (study 301), 2020 (NCT04470427) ; Moderna study 201 100µg, 2020 (NCT04405076) ; McConeghy, 2022 () ; Nguyen, 2022 () ; Amit, 2021 () ; Dagan, 2021 () ; SIREN (HW england), 2021 (ISRCTN11041050) ; Tang, 2021 () ; Thompson, 2021 () ; Agur, 0 () ; Scotland cohort, 0 () ; Shemer, 2021 () ; Accorsi, 2022 () ; Thompson -VISIOn Network (omicron), 2022 () ; Husby (Moderna), 2021 () ; Husby (pfizer), 2021 () ; Patone, 2021 () ; Shasha, 2021 () ; Abu-Raddad, 2022 () ; Kirsebom (UKHSA), 2022 () ; Angel, 2021 () ; Barda, 2021 () ; Bernal (PHE, 19th February 2021), 2021 () ; Bjork, 2021 () ; Burn (Pfizer), 2021 () ; Chodcik, 2021 () ; Edward (pfizer), 2021 () ; EPI-PHARE, 2021 () ; Goldberg, 2021 () ; Haas, 2021 () ; Heymann, 2021 () ; Klein, 2021 () ; Mayo Clinic (Puranik), 2021 () ; McMurphy, 2021 () ; Moderna delta VOC press realease, 2021 () ; Nanduri, 2021 () ; Pawlowski, 2021 () ; Shibli, 2021 () ; Tartof, 2021 (NCT04848584) ; Weekes, 2021 () ; Tande, 0 () ; Lauring, 2022 () ; Patalon, 2022 () ; Southern California (Tseng) - delta, 2022 () ; Southern California (Tseng) - omicron, 2022 () ; Tenforde, 2022 () ; Abu-Raddad, 2021 () ; Chung, 2021 () ; England (Andrews), 2021 () ; Qatar (Tang), 2021 () ; South Africa (Discovery Health, Collie), 2021 () ; Tenforde, 2021 () ; Wan, 2021 () ; Aleman, 2021 () ; Benotmane, 2021 () ; Boyarsky, 2021 () ; Palich, 2021 () ; Rozen-Zvi, 2021 () ; Yanay, 2021 () ; Zadok, 2021 ()

²Asano, 2022 (NCT04568031) ; Com-COV2, 2022 (ISRCTN 27841311) ; Li J, 2022 (NCT04892459) ; AstraZeneca phase 3 US (D8110C00001), 2021 (NCT04516746) ; AstraZeneca phase 3 US (D8110C00001) 6 month follow up, 2021 (NCT04516746) ; Com-COV, 2021 (ISRCTN69254139) ; Fengcai, 2021 (NCT04566770) ; Kulkarni, 2021 (CTRI/2020/08/027170) ; Reindl-Schwaighofer, 2021 () ; Sadoff, 2021 (NCT04436276) ;

AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)*safety*, 2020(); *CanSinophase2*(Zhu), 2020(NCT04341389); *ChAdOx1phase3*(AstraZeneca), 2020(NCT04400838); *RESIST*(SputnikV Gam PHARE), 2022(); *EPIPHARE*(Janssen), 2022(); *EPIPHARE*(Vaxzevria), 2022(); *Hippisley-Cox*, 2021(); *Husby*(Astra), 2021(); *Husby*(janssen), 2021(); *Patone*, 2021(); *Simpson*(ChAdOx1), 2021(); *Nabirova* ³C4591031- first boost, 2021 (NCT04955626); Hall, 2021 (NCT04885907); Pfizer/BioNTech Booster study, 2021 (NCT04713553); COV13, 2022 (); McConeghy, 2022 (); Kislaya, 2022 (); Bar-On, 2021 (); Accorsi, 2022 (); Tan, 2022 (); Abu-Raddad, 2022 (); Arbel, 2021 (); Barda, 2021 (); Mattiuzzi, 2022 (); Ontario (Buchan), 2022 (); Patalon, 2022 (); Tenforde, 2022 (); England (Andrews), 2021 (); Patalon, 2021 (); Sisonke 2 (booster), 2021 (NCT05148845)

⁴PROFISCOV (SinoVac Brazil), 2021 (NCT04456595); Sinopharm Wuhan Vero cell, 2021 (NCT04510207); Xia (66), 2020 (ChiCTR2000032459); CoronaVac Indonesia, 0 (NCT04508075); Sinovac Turkish Trial, 0 (NCT04582344); Ashmawy, 2022 (); Faria, 2021 (); Chile study (Aaros), 0 (); Hitchings, 2021 (); Li, 2021 (); Wan, 2021 (); Bonfa, 2021 (NCT04754698)

⁵Bar-On, 2022 (); Cohen, 2022 (); Arbel / Magen, 2022 (); Regev-Yochay (Comirnaty), 2022 (NCT05231005); Regev-Yochay (Spikevax), 2022 (NCT05231005)

⁶Novavax phase 2 South Africa (2019nCoV-501), 2021 (NCT04533399); Novavax phase 3 UK (2019nCoV-302), 2021 (NCT04583995); Novavax PREVEND-19 phase 3 US (2019nCoV-301), 2021 (NCT04611802); Keech, 2020 (NCT04368988)

⁷South Africa (Discovery Health, Collie), 2021 ()

⁸CombiVacS, 2021 (NCT04860739)